甲磺酸阿帕替尼治疗晚期非小细胞肺癌临床观察

发布时间：2018-04-11 11:33

  本文选题：非小细胞肺癌 + 甲磺酸阿帕替尼　； 参考：《中华肿瘤防治杂志》2017年07期

【摘要】：目的甲磺酸阿帕替尼是一种新型的针对血管内皮生长因子受体2的酪氨酸抑制剂,已被证实是治疗晚期胃癌的有效靶向药物。本研究旨在观察甲磺酸阿帕替尼治疗三线及三线以上晚期非小细胞肺癌的临床疗效及不良反应。方法分析安阳市肿瘤医院2015-02-10-2016-06-10晚期非小细胞肺癌40例的临床资料,所有患者均经组织病理或细胞学确诊。三线及三线以上口服甲磺酸阿帕替尼500mg/d,4周后开始疗效评价。结果 40例患者均可评价疗效,完全缓解(complete response,CR)0例,部分缓解(partial response,PR)9例,疾病稳定(stable disease,SD)19例,疾病进展(progressive disease,PD)12例,客观缓解率(overall response rate,ORR)为22.5%(9/40),疾病控制率(disease control rate,DCR)为70.0%(28/40)。Ki-67表达水平与ORR相关,χ~2=11.335,P=0.003;同时Ki-67表达水平与DCR相关,χ~2=6.427,P=0.04。单因素分析显示,PS评分0~1与PS评分≥2比较中位无进展生存期(progression-free survival,PFS)差异有统计学意义,P=0.022。疗效评价PR、SD、PD 3组间比较中位PFS差异有统计学意义,P=0.017。多变量回归分析显示,PS评分0~1、疗效评价PR可以作为PFS延长的独立预测指标,P0.05。常见不良反应为轻度高血压、蛋白尿和口腔黏膜炎。结论甲磺酸阿帕替尼三线及三线以上治疗晚期非小细胞肺癌安全有效,不良反应轻。
[Abstract]:Objective Apatinib mesylate is a novel tyrosine inhibitor targeting vascular endothelial growth factor receptor 2 and has been proved to be an effective target drug in the treatment of advanced gastric cancer.The purpose of this study was to observe the clinical efficacy and adverse reactions of Apatinib mesylate in the treatment of advanced non-small cell lung cancer (NSCLC).Methods the clinical data of 40 patients with advanced non-small cell lung cancer (NSCLC) in Anyang Cancer Hospital were analyzed. All patients were confirmed by histopathology or cytology.The efficacy was evaluated 4 weeks after oral administration of Apatinib Mesilate 500 mg / d.Results all the 40 patients could evaluate the curative effect. There were 0 cases of complete remission, 9 cases of partial response to PRN, 19 cases of stable disease, 12 cases of progressive disease, 12 cases of progressive disease, 9 cases of partial response, 19 cases of stable disease and 12 cases of progressive disease.Univariate analysis showed that there was a significant difference in the median progression-free survival PFSs between PS score 0 and PS score 鈮，

本文编号：1735862